strategic alternatives
Enzo Biochem Fiscal Q3 Revenues Fall 20 Percent; Firm Examining Strategic Alternatives
Enzo has engaged investment bank Jefferies to evaluate strategic alternatives for the company and its various divisions and assets.
OraSure Misses COVID-19 Antigen Test Sales Guidance; Announces CEO Departure, Strategic Review
OraSure expects to miss its full-year rapid COVID-19 antigen test sales estimate by $10 million, and will now undertake a strategic review.
Fluidigm Q3 Revenues Drop 29 Percent on Supply Chain Issues, Waning COVID-19 Testing
The company also lowered its full-year financial guidance and said its board of directors is undertaking a strategic review to maximize shareholder value.
Admera Health Seeks to Divest Pharmacogenomics, Clinical Services Business
The company will continue to offer research services for biopharma customers but is hoping a strategic partner can take over its clinical portfolio.
Qiagen Completes Strategic Review, Rejects Acquisition Offers
The firm had received interest from unnamed potential acquisition partners following the departure of its CEO, but it has decided to remain as a standalone business.
Jun 10, 2019
Enzo Biochem Fiscal Q3 Revenues Decline 22 Percent
Apr 2, 2018
Cancer Genetics Q4 Revenues Grow 4 Percent
Nov 19, 2012